Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ROS1 rearrange ROS1 L2086F |
Therapy | Cabozantinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ROS1 rearrange ROS1 L2086F | lung adenocarcinoma | predicted - sensitive | Cabozantinib | Case Reports/Case Series | Actionable | In a clinical case study, Cometriq (Cabometyx, cabozantinib) treatment resulted in a partial response in a heavily pretreated patient with metastatic lung adenocarcinoma harboring a ROS1 rearrangement with ROS1 L2086F (PMID: 39091594). | 39091594 |
PubMed Id | Reference Title | Details |
---|---|---|
(39091594) | L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report. | Full reference... |